INTRODUCTION {#s1}
============

Trichorhinophalangeal syndrome (TRPS) is a rare disorder, inherited in an autosomal dominant pattern, which is characterized by facial (bulbous nose, long philtrum, thin upper lip, and prominent ears), ectodermal (sparse, thin, and depigmented hair, thick eyebrows with lateral thinning, and dystrophic nails), and skeletal abnormalities (short stature, short hands and feet, hip dysplasia, and cone-shaped epiphyses at the phalanges) ([@MCS004655ZEPC15]). Two distinct clinical types have been described for TRPS, with type I (TRPSI; OMIM\#190350) caused by pathogenic variants in *TRPS1*, and type II (TRPSII, also known as Langer--Giedion syndrome; OMIM\#150230). TRPSI is caused by loss of function mutations in *TRPS1* and clinical features present with significant phenotypic variability among affected individuals and family members ([@MCS004655ZEPC16]), including a form characterized by severe brachydactyly, previously proposed as a separate entity (TRPSIII; OMIM\#190351) ([@MCS004655ZEPC20]; [@MCS004655ZEPC14]). TRPSII stems from contiguous gene deletions encompassing *TRPS1*, *RAD21*, and *EXT1* ([@MCS004655ZEPC15]). In addition to clinical features described in TRPSI, individuals with TRPSII present with exostoses and an increased risk of intellectual disability ([@MCS004655ZEPC9]).

*TRPS1* (zinc-finger transcription factor TRPS1; OMIM\#604386) is a seven-exon transcriptional repressor involved in the regulation of chondrocyte and perichondrium development ([@MCS004655ZEPC18]). The most common pathogenic variants found in *TRPS1* are nonsense and frameshift variants scattered along exons 4--7, which effectively truncate/alter the protein sequence ([@MCS004655ZEPC16]). Intragenic and full gene deletions have also been reported with variable breakpoints, together with missense variants primarily clustering in exon 6 ([@MCS004655ZEPC16]). In contrast to the more frequent deletions and single-nucleotide variants (SNVs), duplication events involving *TRPS1* are rare and mostly involve single or few (\<10) nucleotides ([@MCS004655ZEPC16]). Only a large pathogenic duplication of at least 600 bp (c.2097−?\_c.2700+?dup) in *TRPS1* has been reported in an individual presenting with TRPSI, but no further characterization of this variant at the molecular or protein level has been reported ([@MCS004655ZEPC16]). At the nucleotide level, duplication breakpoints could disrupt *TRPS1* sequence or generate gene fusions, and when intragenic, they could give rise to new transcripts through splicing alterations or truncate proteins by introducing stop codons ([@MCS004655ZEPC19]), all of which could contribute to TRPS pathogenesis.

In this report, we present an 11-yr-old male with a history of short stature, mild facial dysmorphism, and ectodermal and skeletal abnormalities consistent with a diagnosis of TRPSI. Chromosomal microarray analysis identified a de novo intragenic ∼36.3-kbp duplication affecting exons 2--4 of *TRPS1* (NM_014112). Molecular characterization of the duplication by mate-pair sequencing (MPseq) revealed it to be in direct tandem orientation, and RNA sequencing (RNA-seq) discovered abnormal transcripts including the duplicated exons leading to out-of-frame products with predicted protein truncations. The present study is the first full characterization of an intragenic *TRPS1* duplication leading to TRPSI and a valuable example for the study of intragenic tandem duplication effects in genomic transcriptional outputs.

RESULTS {#s2}
=======

Case Presentation {#s2a}
-----------------

An 11-yr-old male (II-3, [Fig. 1](#MCS004655ZEPF1){ref-type="fig"}A) was referred for genetic evaluation because of a history of nonspecific skin hyperpigmentation involving left shoulder and axilla, short stature (139.5 cm, 5.1%, *Z* = −1.63 based on CDC length-for-age data), and scoliosis ([Fig. 1](#MCS004655ZEPF1){ref-type="fig"}B,C). He was mildly dysmorphic with a bulbous nose, prominent ears, a thin upper lip, and a long philtrum; his hair was noted to be fine and sparse, and his eyebrows were thick with lateral rarefaction. X-ray imaging revealed the presence of cone-shaped epiphyses at the phalanges ([Fig. 1](#MCS004655ZEPF1){ref-type="fig"}D,E). Similar skin lesions were present in his otherwise healthy mother. None of these features were present in his fraternal twin brother (II-4) or other full and half siblings ([Fig. 1](#MCS004655ZEPF1){ref-type="fig"}A).

![(*A*) Family pedigree for the analyzed proband. Proband is indicated with a black arrowhead. Numbers underneath indicate years of age. The clinical features of proband include (*B*) skin hyperpigmentation, (*C*) scoliosis, and (*D*,*E*) cone-shaped epiphyses at the phalanges as indicated with the white circle (*E* is the zoom-in view of *D*).](MCS004655Zep_F1){#MCS004655ZEPF1}

Genetic Testing {#s2b}
---------------

A next-generation sequencing (NGS) RASopathy panel targeting 18 genes (*NF1*, *SPRED1*, *LZTR1*, *PTPN11*, *PPP1CB*, *BRAF*, *CBL*, *HRAS*, *KRAS*, *NRAS*, M*AP2K1*, *MAP2K2*, *RAF1*, *RIT1*, *RASA2*, *SHOC2*, *SOS1*, and *SOS2*) and deletion/duplication analysis of *LZTR1*, *NF1*, and *SPRED1* (University of Alabama at Birmingham) was performed because of the proband\'s short stature and familial skin hyperpigmentation, the result of which was negative. Subsequent chromosome microarray (CMA) testing of the proband and his parents revealed the presence of a heterozygous 36.3-kbp duplication at 8q23.3 in the proband (arr\[hg19\] 8q23.3(116603667_116640019) × 3 dn), including exons 2--4 from *TRPS1* (NM_014112) ([Fig. 2](#MCS004655ZEPF2){ref-type="fig"}A; [Supplemental Fig. 1A,B](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004655/-/DC1)). Parental CMA studies demonstrated that this duplication was not inherited from either parent, and it was therefore classified as a de novo event. Given the overlap between the proband\'s phenotype and TRPSI, it was hypothesized that the duplication could result in the functional disruption of the duplicated allele. To distinguish between a tandem and an insertional duplication, we analyzed the proband\'s blood using MPseq, a specialized NGS technique for the detection of structural rearrangements and copy-number abnormalities ([@MCS004655ZEPC3]; [@MCS004655ZEPC6]; [@MCS004655ZEPC22]). MPseq established the duplication to be in direct tandem orientation within *TRPS1* ([Supplemental Fig. 1C,D](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004655/-/DC1)), with estimated breakpoints at Chr 8:115,591,898--115,628,547 (hg38). The identified MPseq duplication breakpoints were confirmed with Sanger sequencing and mapped to Chr 8:115,591,769--115,628,731 (hg38) ([Table 1](#MCS004655ZEPTB1){ref-type="table"}). Analysis of the Sanger sequence revealed microhomology between the rearranged segments and at the breakpoint junction, with a nearby sequence corresponding to transposon repetitive elements (SINE and hAT-Charlie) ([Supplemental Data](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004655/-/DC1)).

![Abnormal transcripts associated with intragenic duplication in *TRPS1*. (*A*) Schematic of *TRPS1* (NM_014112) with tandem duplication of exons 2--4 as found in proband. The observed splicing patterns are shown by lines connecting the exons, and abnormal splicing is shown in bold black lines. Asterisks indicate premature termination codons caused by abnormal splicing in duplicated region. (*B*) Schematic of TRPS1 with reported domains for the reference protein and for the predicted truncated proteins from each abnormal splicing event (product a and b from *A*). Integrative Genomics Viewer (IGV) screenshots of the RNA-seq paired reads supporting abnormal splicing aligned to the proband-specific synthetic reference sequence of (*C*) product a: exons 4--2--3, and (*D*) product b: exons 4--3 without intronic sequence included.](MCS004655Zep_F2){#MCS004655ZEPF2}

###### 

Variant table

  Gene       Chromosome  HGVS variant                     Variant type   Predicted effect (ACMG)   MPseq coverage   Genotype (heterozygous/homozygous)   Parent of origin   Comments
  --------- ------------ -------------------------------- -------------- ------------------------- ---------------- ------------------------------------ ------------------ ---------------------------------
  *TRPS1*        8       GRCh38 g.115591769\_ 115628731   Duplication    Likely pathogenic         24×              Heterozygous                         De novo            Variant was confirmed by Sanger

Functional Studies {#s2c}
------------------

To assess the functional impact of the intragenic duplication on *TRPS1* transcription, we performed NGS whole-transcriptome sequencing from blood RNA. The schematic of the duplicated exons is shown in [Figure 2](#MCS004655ZEPF2){ref-type="fig"}A and protein domains in [Figure 2](#MCS004655ZEPF2){ref-type="fig"}B. We observed in proband\'s sample and unrelated samples (data not shown) skipping of exon 2, which occurs in a known transcript (NM_001282902) that is lowly expressed in the GTEx data ([www.gtexportal.org](www.gtexportal.org)). We created a proband-specific coding reference including exons 4--2--3 consecutively together and another reference for exons 4--3. By aligning the RNA-seq reads to the synthetic reference sequences ([Fig. 2](#MCS004655ZEPF2){ref-type="fig"}C,D, respectively), the reads supporting these aberrant junctions caused by the duplication event in proband can be visualized. A total of 52 read pairs support splicing from exon 4 to either exon 2 or 3, with 13 of those having one read in the pair spanning the exon 4--2 junction and 15 having a one read in the pair spanning the exon 4--3 junction. The consequence to the transcript in either event is a premature termination codon ([Fig. 2](#MCS004655ZEPF2){ref-type="fig"}A). Exon 2 has 121 bp of 5′ UTR and when splicing from exon 4, translates to 16 amino acids followed by a premature termination codon. When splicing from exon 4 to 3, the transcript is out of frame and translates to 14 amino acids and a premature termination codon in the duplicated exon 3. At the exon level, reads per kilobase of transcript per million mapped reads (RPKM) revealed a higher number of reads mapping to exons 2--4 compared to a cohort of 127 differently affected individuals or unaffected relatives of subjects with suspected monogenetic disease ([Fig. 3](#MCS004655ZEPF3){ref-type="fig"}). An expression analysis using OUTRIDER ([@MCS004655ZEPC2]) showed only a modest increase in expression for *TRPS1* (0.38 log~2~ fold change), most likely owing to the presence of the third copy of exons 2--4 (∼50% of *TRPS1* nucleotides) being transcribed and leading to additional reads contributing to overall gene expression. However, the nonduplicated exons in *TRPS1* support normal expression levels and suggest the abnormal transcript with the duplicated exons may be escaping nonsense-mediated decay (NMD) that would be predicted from the premature termination codons. Given the proband\'s phenotype and the derived functional evidence of the intragenic duplication effect on the *TRPS1* transcript, the proband was diagnosed with TRPSI.

![Gene expression analysis. (*A*) *TRPS1* exonic expression levels in blood RNA of the proband compared to a cohort of 127 individuals differently affected with, or unaffected individuals related to individuals with, suspected rare monogenetic disease. (*B*) Gene expression changes called by OUTRIDER in this individual compared to the cohort represented as −log~10~(unadjusted *P*-value) versus *Z*-score.](MCS004655Zep_F3){#MCS004655ZEPF3}

DISCUSSION {#s3}
==========

We described a novel 36.3-kbp intragenic duplication in *TRPS1* in an individual presenting with the classic ectodermal, facial, and skeletal abnormalities of TRPSI. CMA and MPseq analyses showed the duplication to be de novo and in direct tandem orientation within *TRPS1* in the affected subject, effectively duplicating exons 2--4. Although more than 130 pathogenic variants have been reported in *TRPS1*, to our knowledge, this is the first characterization of a large intragenic duplication in *TRPS1* associated with TRPSI.

The clinical features of TRPSI are caused by haploinsufficiency of *TRPS1*, a transcriptional repressor involved in the regulation of chondrocyte and perichondrium development. The identified intragenic duplication of exons 2--4 was shown to produce abnormal transcripts with splicing patterns including exons 4--2 and 4--3. Both of these abnormal transcripts are predicted to (1) undergo NMD or (2) produce a likely nonfunctional protein missing the GATA zinc finger, the IKAROS-like zinc finger, and the nuclear localization signal (NLS) ([Fig. 2](#MCS004655ZEPF2){ref-type="fig"}B). In a NMD scenario, a lower-than-average number of mapped reads was expected for the transcripts. RPKM values of the duplicated exons were higher compared to normal male controls, whereas nonduplicated exons had RPKM ranges similar to controls. Such observations suggest that the aberrant intragenic duplication transcripts may not undergo NMD; further inspection of RNA-seq data failed to reveal any informative sequence variants for detecting allelic expression bias that would result from one transcript undergoing NMD. Either the allele with the duplicated exons is undergoing NMD, but overall gene transcription is up-regulated to compensate, or the abnormal transcripts escape NMD, are expressed at normal levels, and are translated into truncated nonfunctional protein lacking the functional GATA and IKAROS-like zinc fingers necessary for its correct genomic binding and repression activities. Such truncations can effectively cause functional haploinsufficiency of *TRPS1* in the reported individual and thus be a cause of TRPSI. Future proteomic experiments could evaluate the presence of truncated versions lacking the aforementioned domains.

Altogether, intragenic duplications within *TRPS1* can have major clinical significance as illustrated in the currently studied individual. Identification and molecular characterization of other intragenic *TRPS1* duplications will be necessary to assess genotype--phenotype correlations and to discover specific sites within the gene that are prone to further or recurrent chromosome rearrangements, as seen from our discovery of microhomology at the reported duplication junction. Microhomology-mediated mechanisms such as fork stalling and template switching (FoSTeS) ([@MCS004655ZEPC11]) and microhomology-mediated break-induced replication (MMBIR) ([@MCS004655ZEPC5]) have been extensively associated with genomic germline duplications and deletions and other complex rearrangements. Both FoSTeS and MMBIR are plausible mechanisms to explain the origin of the intragenic *TRPS1* duplication reported herein, given the detected junction microhomology and the presence of transposon sequences (SINE and hAT-Charlie) in the vicinity of the breakpoints, which can prime replication strand invasions upon double-strand breaks.

As we hope to have illustrated with this study, comprehensive molecular characterization of intragenic duplications is essential for the investigation of their pathogenicity and estimating potential recurrence risks. As NGS becomes a routine clinical test in clinical diagnosis, we surmise that additional intragenic duplications involving *TRPS1* and many more genes will be uncovered, and their impact on protein structure assessed and correlated to diverse forms of human disease.

MATERIALS AND METHODS {#s4}
=====================

Approval for this study was received by the Mayo Clinic Institutional Review Board, application number 12-009346; participants were consented for release of data included in this study. Chromosome microarray was performed on peripheral blood using the CytoScan HD Suite (Thermo Fisher Scientific), which evaluates allelic and copy-number information, according to the manufacturer\'s protocol. CMA data was analyzed using ChAS software version 3.1. MPseq was performed on DNA extracted from peripheral blood using AutoPure LS (QIAGEN). MPseq libraries were prepared using Nextera Mate Pair Library Preparation Kit (Illumina) and subsequently purified and processed for short-read library preparation using TruSeq DNA Library Prep kit (Illumina). Purified libraries were sequenced in an Illumina HiSeq 2500 using RapidRun mode to obtain 101-bp reads. MPseq data was processed with BIMAv3 and analyzed with SVAtools version 0.24.9. Polymerase chain reaction (PCR) experiments were performed to amplify breakpoint junctions identified by MPseq.

RNA was isolated using the miRNeasy Mini Kit (QIAGEN) following the standard protocol from blood drawn in a PAXgene Blood RNA Tube (QIAGEN). RIN and DV200 values were determined for starting RNA concentrations using the Agilent Bioanalyzer or TapeStation. RNA libraries were prepared according to the manufacturer\'s instructions for the TruSeq RNA Access Library Prep Kit (Illumina). Coding regions of the transcriptome were captured by pooling four of the cDNA libraries at 200 ng each following the manufacturer\'s instructions for the TruSeq RNA Access Library Prep Kit (Illumina). The concentration and size distribution of the final libraries were determined on an Agilent Bioanalyzer DNA 1000 chip (Agilent Technologies). A final quantification, using Qubit fluorometry (Invitrogen), was performed to confirm sample concentration.

Libraries were sequenced at ∼65 million fragment reads per sample (4 samples/lane) following Illumina\'s standard protocol using the Illumina cBot and HiSeq 3000/4000 PE Cluster Kit. The flow cells were sequenced as 100 × 2 paired-end reads on an Illumina HiSeq 4000 using HiSeq 3000/4000 sequencing kit and HCS v3.3.20 collection software. Base calling was performed using Illumina\'s RTA version 2.5.2.

RNA-sequencing analysis was performed using MAP-RSeq ([@MCS004655ZEPC7]). Reads were aligned to the human genome (hg19) and transcriptome using TopHat2 ([@MCS004655ZEPC8]) running Bowtie (v1) ([@MCS004655ZEPC10]). Gene- and exon-level read counts were generated using HiSeq ([@MCS004655ZEPC1]) and BEDTools ([@MCS004655ZEPC21]), respectively.

Custom reference creation: Two custom human reference sequences were constructed to represent the aberrant transcripts arising from the tandem duplication of *TRPS1* exons 2--4. Constituent exon sequences were extracted from the UCSC hg19 FASTA sequence utilizing genomic coordinates for RefSeq transcript NM_014112.4. FASTA sequence for the exons were concatenated in the order Exon 4 → Exon 2 → Exon 3 and Exon 4 → Exon 3 in the 5′ to 3′ direction, mimicking the expected aberrant juxtaposition of the exons in the final transcripts. All other *TRPS1* exons were excluded from the custom reference to ensure specificity of alignments supporting the aberrantly formed splice junctions. Alignment: Cutadapt ([@MCS004655ZEPC17]) was used to remove poly(A) tails from raw RNA-seq reads. Alignment to the custom reference sequence was performed using BWA MEM ([@MCS004655ZEPC12]) with default parameters. SAMTools ([@MCS004655ZEPC13]) was used to remove reads with multiple mappings or improper read-pairing or to insert sizes varying from the expected range. Read pairs containing one mate crossing an aberrantly formed splice junction by fewer than 10 bases were filtered to prevent nonspecific alignments that might align with equal homology with the normal transcript. Integrative Genomics Viewer (IGV) ([@MCS004655ZEPC23]) was used to generate snapshots of the final alignments. A custom annotation track was created to enable identification of exon order in the custom reference.

Outlier expression analyses: Expression counts and RPKMs were computed as above for a cohort of 128 samples from the Mayo Clinic Service Line 2 for rare and undiagnosed diseases. Genes with low expression in blood were filtered out. Specifically, genes whose 0.95 quantile FPKM was \<1 or whose counts were 0 in more than one-quarter of the samples were excluded from the analysis. Outlier expression analysis was then performed using OUTRIDER ([@MCS004655ZEPC2]) with the Benjamini--Hochberg correction for multiple comparisons, which provided confounder-corrected *z*-scores, log~2~ fold changes, *P*-values, and adjusted *P*-values.
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